
biotech discov
invent manufactur commerci medicin
treat seriou diseas
eylea challeng step market maintain
hold lower pt
take-away regn core eylea revenu may pressur due fda approv
nv beovu wet relat macular degener competit may
manag nv beovu may provid less frequent dose vs eylea await real-
world experi drug
nv beovu approv wet quarterli dose await real-world dose
nv beovu may dose frequent everi month balanc
advantag eylea dose interv importantli beovu design around desir
dose interv around optim efficaci real world physician
focu efficaci beovu first optim dose interv accordingli beovu
maintain patient quarterli dose phase trial vs month dose
eylea show non-inferior efficaci
beovu phase trial demonstr non-inferior eylea
beovu demonstr non-inferior eylea two phase trial less frequent
dose may give advantag nv product phase studi beovu
found non-inferior mean chang best-correct visual acuiti year
beovu also demonstr greater reduct central subfield thick earli
week year furthermor fewer patient intra-retin and/or sub-retin
fluid marker diseas activ safeti profil beovu eylea
found similar
eylea still addit indic beovu point strength
although beovu enter wet market think eylea still sever point
strength could slow revenu eros eylea current still hold two addit
indic beovu macular edema follow retin vein occlus
diabet retinopathi diabet macular edema addit indic
still provid moat competitor furthermor physician may
accustom eylea current patient may eylea
want chang lastli could monetari invent physician eylea
inject frequent doctor would given often
maintain hold lower pt
lower pt base deterior investor
sentiment ad risk addit competitor largest product
factor move pe multipl alreadi take account
competit eylea revenu model base view consensu
number bit high maintain hold rate note sever
headwind compani includ dupix patent ipr/litig continu
price concern eylea medicar part price initi addit eylea
competit join fray continu expect strong growth dupix
moder growth eylea may diminish competit product obtain greater
market share time
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
hold unchang target price octob
date eylea npdr patient w/o dme completedpdufa date praluent cardiovascular risk reductioncompletedpdufa date praluent first-lin hyperlipidemia completedregulatori regulatori decis libtayo advanc cscccompletedpdufa date dupix adolesc ad completeddata data dupix pediatr non-gaap epsp multipl figur revenu build
hold unchang target price octob
fy producteyleau ex-u arcalystu ex-u revenues- libtay ex-u revenues- net product sale book praluentu ex-u ww zaltrapex-u us ww kevzarau ex-u dupixentu atop uncontrol asthma- ex-u atop uncontrol asthma- figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
hold unchang target price octob
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch reimburs sanofi bayer teva option non-reimburs sell gener option expens sg ex-opt collabor total oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom tax rate tax expens benefit net incom loss adjust net net incom loss ep fulli ep fulli epsbas share dilut share outstand dilut share outstand figur balanc sheet
hold unchang target price octob
fy pharmaceut balanc sheetasset cash equival market secur account receiv trade account receiv sanofi account receiv bayer defer tax assets- prepaid expens current asset total current asset restrict cash market secur market secur properti plant equip cost net accumul defer tax asset total asset liabil account payabl accru expens defer revenu sanofi current portion defer revenu current portion facil leas oblig current portion current liabilities- total current liabil defer revenu sanofi defer revenu facil leas oblig long term liabil total liabil commit conting total stockhold equiti total liabil stockhold equiti figur statement
hold unchang target price octob
fy statement flow net incom adj reconcil net loss net cash use provid oper activities- depreci non-cash compens non-cash interest expense- loss earli extinguish debt- net realiz loss gain market securities- non-cash charg expens defer chang asset liabil decreas increas account increas increas decreas prepaid expens decreas increas defer increas account payabl accru expens total flow purchas market sale matur market purchas restrict market securities- decreas increas restrict cash- capit increas restrict cash- flow repurchas repay note payable- proce connect facil leas obligations- payment connect facil leas obligations- net proce issuanc common payment common stock tender employe tax payment connect reduct outstand warrants- net proce issuanc convert debt- proce connect issuanc warrants- payment connect capit leas obligations- payment connect convert debt- payment connect purchas convert note hedges- excess tax benefit stock-bas compensation- repurchas common flow net increas cash cash cash equival begin cash equival end regeneron
